Pulmonary Arterial Hypertension: Clinical Trials

68 completed, 28 terminated, 17 recruiting, 8 unknown. 139 Phase 2, 14 Phase 1, 9 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	139	Completed 68, Terminated 28, Recruiting 17, Unknown 8, Not yet recruiting 7, Withdrawn 7, Active not recruiting 4
Phase 1	14	Completed 6, Recruiting 3, Unknown 2, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 3	9	Completed 4, Active not recruiting 2, Recruiting 1, Terminated 1, Unknown 1

Follow Pulmonary Arterial Hypertension: new trials by email Literature Review of Pulmonary Arterial Hypertension trials Research Report on Pulmonary Arterial Hypertension

Trials (filtered) newest first · largest first

All 139 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension Dextrose, Sildenafil 20mg - Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)	Phase 2 / Phase 3	Recruiting	Silvia Ulrich	20	2026-10-26	2026-11-04
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension GLP-1 agonist - Pulmonary Arterial Hypertension	Phase 2	Not yet recruiting	Imperial College London	32	2026-10-01	2026-07-30
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) NS-863 Low Dose, NS-863 High Dose, NS-863 Placebo - Pulmonary Arterial Hypertension	Phase 2	Recruiting	NS Pharma, Inc.	135	2026-09-29	2026-10-28
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032) Sotatercept - Pulmonary Arterial Hypertension	Phase 2	Recruiting	Merck Sharp & Dohme LLC	6	2026-09-17	2026-10-06
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension CS1, Placebo - Pulmonary Arterial Hypertension	Phase 2	Not yet recruiting	Cereno Scientific AB	126	2026-09-15	2026-08-12
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension 2-HOBA - Pulmonary Arterial Hypertension	Phase 2	Not yet recruiting	Vanderbilt University Medical Center	12	2026-09-01	2026-06-17
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults HS235, Placebo - Pulmonary Arterial Hypertension	Phase 1 / Phase 2	Recruiting	35Pharma Inc., a GSK company	90	2026-08-19	2026-10-30
Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH [68Ga]Ga-FAPI PET/CT, [68Ga]Ga-MAA PET/CT - Pulmonary Arterial Hypertension (PAH)	Phase 1 / Phase 2	Not yet recruiting	University Hospital, Brest	15	2026-07-15	2026-06-16
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) Tiprelestat (5 mg), Placebo (1 mL 0.9% saline solution), Tiprelestat (10 mg) - Pulmonary Arterial Hypertension (PAH)	Phase 2	Not yet recruiting	Stanford University	90	2026-07-01	2026-05-22
SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg, Sotatercept - Pulmonary Arterial Hypertension (PAH)	Phase 2	Not yet recruiting	Philipps University Marburg	25	2026-07-01	2025-12-05
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia DIAG723, Placebo - Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension	Phase 1 / Phase 2	Recruiting	Diagonal Therapeutics, Inc.	93	2026-06-04	2026-09-08
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) REGN13335, Placebo - Pulmonary Arterial Hypertension (PAH)	Phase 2	Recruiting	Regeneron Pharmaceuticals	99	2026-05-06	2026-10-26
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension Treprostinil - Pulmonary Arterial Hypertension (PAH)	Phase 2	Not yet recruiting	Shanghai Zhongshan Hospital	32	2025-10-31	2025-09-17
129 Xenon Imaging in Patients Treated With Sotatercept 129Xe Hyperpolarized - Pulmonary Hypertension, Pulmonary Arterial Hypertension	Phase 2	Recruiting	Bastiaan Driehuys	14	2025-10-27	2026-02-24
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) ROC-101 - Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease	Phase 2	Recruiting	AllRock Bio, Inc.	40	2025-10-01	2026-10-08
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) IkT-001Pro, Placebo - Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)	Phase 2	Withdrawn	Inhibikase Therapeutics		2025-06-30	2025-06-13
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension Empagliflozin 10 MG, Placebo - Pulmonary Arterial Hypertension	Phase 2	Recruiting	Gustavo A Heresi, MD, MS	78	2025-06-26	2026-08-13
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) Sotatercept, Background PAH Therapy - Pulmonary Arterial Hypertension	Phase 2	Active not recruiting	Merck Sharp & Dohme LLC	130	2025-05-12	2025-12-05
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension APL-9796 - Pulmonary Arterial Hypertension	Phase 2	Recruiting	Apollo Therapeutics Ltd	48	2025-04-09	2026-05-11
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) Sotatercept, Background PAH Therapy - Pulmonary Arterial Hypertension	Phase 2	Completed	Merck Sharp & Dohme LLC	164	2024-11-14	2025-12-05

Showing 20 of 139. Sign in to see all of them.

Narrower conditions

Hypertension, Pulmonary (40)  ·  Familial Primary Pulmonary Hypertension (10)  ·  Lung Diseases (5)  ·  Lung Diseases, Interstitial (5)  ·  Cardiovascular Diseases (4)  ·  Connective Tissue Diseases (4)  ·  Idiopathic Pulmonary Fibrosis (4)  ·  Dyspnea (3)  ·  Heart Failure (3)  ·  Hypertension (3)  ·  Vascular Diseases (3)  ·  Cough (2)  ·  Dizziness (2)  ·  Motor Activity (2)

Broader conditions

Respiratory Tract Diseases (138)  ·  Lung Diseases (134)  ·  Hypertension, Pulmonary (99)  ·  Cardiovascular Diseases (42)  ·  Vascular Diseases (39)  ·  Hypertension (38)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Pathologic Processes (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Heart Diseases (4)  ·  Hemic and Lymphatic Diseases (4)  ·  Respiration Disorders (4)  ·  Signs and Symptoms (4)  ·  Signs and Symptoms, Respiratory (4)

Interventions

ACE-011 (7)  ·  ambrisentan (5)  ·  treprostinil (5)  ·  Iloprost (4)  ·  CXA-10 (3)  ·  Carvedilol (3)  ·  Anastrozole (2)  ·  BID protein, human (2)  ·  Bosentan (2)  ·  Fluoxetine (2)  ·  Imatinib Mesylate (2)  ·  Injections (2)  ·  Nitric Oxide (2)  ·  Sildenafil Citrate (2)  ·  Tadalafil (2)

Sponsors

Novartis Pharmaceuticals (7)  ·  Actelion (6)  ·  Merck Sharp & Dohme LLC (5)  ·  United Therapeutics (5)  ·  University of Pennsylvania (5)  ·  Bastiaan Driehuys (4)  ·  GlaxoSmithKline (4)  ·  Lung Biotechnology PBC (4)  ·  Gilead Sciences (3)  ·  Imperial College London (3)  ·  Insmed Incorporated (3)  ·  Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (2)  ·  Aires Pharmaceuticals, Inc. (2)  ·  Altavant Sciences GmbH (2)  ·  Bayer (2)

Countries

United States (94)  ·  Germany (39)  ·  United Kingdom (33)  ·  Spain (27)  ·  France (25)  ·  Australia (21)  ·  Canada (20)  ·  Italy (17)  ·  Belgium (16)  ·  Poland (16)  ·  Japan (12)  ·  Argentina (11)  ·  Czechia (11)  ·  Austria (10)  ·  China (10)

Top investigators

Sudarshan Rajagopal, MD, PhD (3)  ·  Adaani E Frost, M.D. (2)  ·  Aimee Smart (2)  ·  Cynthia Madden, MD, MPH (2)  ·  Ed Parsley, DO (2)  ·  Pascale Blais-Lecours, PhD (2)  ·  Roham Zamanian, MD (2)  ·  Steeve Provencher, MD, MSc (2)  ·  Steven M Kawut, MD (2)  ·  Steven M Kawut, MD, MS (2)  ·  Theo Danoff, MD (2)

Results publications

PMID 19705340, PMID 20530034, PMID 20581169, PMID 21146637, PMID 21593252, PMID 22362844, PMID 22362846, PMID 23547564, PMID 24177203, PMID 24431095, PMID 24930531, PMID 25615959, PMID 26501464, PMID 27390285, PMID 27602993, PMID 28329240, PMID 28610669, PMID 28893866, PMID 28963118, PMID 30808080, PMID 31202506, PMID 31314997, PMID 31391223, PMID 33651671, PMID 33735594, PMID 33789009, PMID 33856964, PMID 34107229, PMID 34107236, PMID 34379314, PMID 34425071, PMID 34588193, PMID 36041750, PMID 36579617, PMID 36923571, PMID 37332660, PMID 37732786, PMID 38532768, PMID 38572639, PMID 38747680, PMID 39255991, PMID 39307144, PMID 39761829, PMID 40035659, PMID 40766123, PMID 40788460, PMID 41223909, PMID 41429287, PMID 41738079, PMID 41973984

NIH funding

2018 (3), 2023 (3), 2017 (2), 2005 (1), 2014 (1), 2015 (1), 2016 (1), 2025 (1), P01HL103455 (1), R01HL082895 (1), R01HL134905 (1), R61HL142539 (1), R61HL167848 (1), U24HL180994 (1), UG3HL175041 (1)